Respiratory Drug Delivery Technologies Market Report 2022-2032 – Yahoo Finance
Strategist Michael Antonelli joins Jared Blikre to break down the Fed decision and more at 2 P.M. ET Wednesday.
Forecasts by Product (Formulations, Devices), by Type (Dry Powder, Suspension Aerosol, Solution Aerosol), by Product Type (Metered Dose Inhalers (MDIS), Dry Powder Inhalers (DPIs), Nebulizers, Accessories), by Nebulizers Type (Soft Mist Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers), by Canister Type (Plain Canisters, Coated Canister), by Application (Asthma, COPD, Cystic Fibrosis, Others), by End-user (Homecare, Hospitals & Clinics, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios
New York, June 21, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Respiratory Drug Delivery Technologies Market Report 2022-2032” – https://www.reportlinker.com/p06288089/?utm_source=GNW
The Respiratory Drug Delivery Technologies Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The Rise in Prevalence of Respiratory Diseases, Technological Advancements, And Outbreak of COVID-19 Pandemic Are Driving the Market Growth
Some of the major forces propelling the global respiratory drug delivery technologies market include an increase in prevalence and incidence of respiratory diseases, technological advancements in respiratory drug delivery, and the outbreak of the Covid-19 pandemic. Furthermore, the use of nanoparticles and polymeric carriers in respiratory drug delivery systems is expected to propel the overall market. Some trends in the field are indicated by recent advances in inhaled devices and formulations. High-dose dry powder alternatives are becoming increasingly popular with nebulized formulations and would be supported by the development of new high-dose (> 100 mg) DPI (Dry Powder Inhalers) variants. Single-use disposable dry powder inhalers can be helpful in the treatment of various respiratory diseases including infectious diseases.
Nebulizers, particularly software-aided systems using smart cards and an electronic control unit that can accurately direct lung deposition and total dosage, will play a crucial role in novel cancer therapies and improve the reliability of inhaled therapy clinical trials. A greater proportion of future formulations of aerosols is also expected to involve repurposed drugs.
The use of nanoparticles in pulmonary drug delivery formulations for DPI (Dry Powder Inhalers) remains a hot topic. Nanoparticles of the same drug were found to have significantly less impact on the oropharyngeal region and higher peripheral deposition in humans compared to micronized salbutamol sulfate, suggesting greater local bioavailability for a sustained period of time due to their smaller size.
Barriers of Respiratory Drugs Delivery
The respiratory system has evolved self-defence methods to keep inhaled medication particles out of the lungs and to eliminate or inactivate them once established and hence pulmonary drug administration is relatively difficult. In addition to mechanical, pharmacological, and immunological barriers, behavioural barriers such as compliance and inhaler technique have a negative impact on pulmonary medication delivery. Strategies for mitigating the effects of these barriers include the use of inhaler devices and compositions that efficiently deliver medicine to the lungs, adequate inhaler technique, and increased patient education. If respiratory drug delivery devices are used appropriately, the pulmonary route offers enormous opportunities, often meeting unmet clinical requirements.
What Questions Should You Ask before Buying a Market Research Report?
• How is the respiratory drug delivery technologies market evolving?
• What is driving and restraining the respiratory drug delivery technologies market?
• How will each respiratory drug delivery technologies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each respiratory drug delivery technologies submarket develop from 2022 to 2032?
• What will be the main drivers for the overall market from 2022 to 2032?
• Will leading respiratory drug delivery technologies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the respiratory drug delivery technologies projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of respiratory drug delivery technologies projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the respiratory drug delivery technologies market?
• Where is the respiratory drug delivery technologies market heading? And how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and? C-suite?
You need to discover how this will impact the respiratory drug delivery technologies market today, and over the next 10 years:
• Our 587-page report provides 456 tables and 454 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the respiratory drug delivery technologies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising respiratory drug delivery technologies prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
By Product
• Formulations
• Devices
By Type
• Dry Powder
• Suspension Aerosol
• Solution Aerosol
By Product Type
• Metered Dose Inhalers (MDIS)
• Dry Powder Inhalers (DPIS)
• Nebulizers and Accessories
By Nebulizers Type
• Soft Mist Nebulizers
• Jet Nebulizers
• Ultrasonic Nebulizers
By Canister Type
• Plain Canisters
• Coated Canister
By Application
• Asthma
• COPD
• Cystic Fibrosis
• Others
By End User
• Homecare
• Hospitals & Clinics
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 21 leading national markets:
North America
• U.S.
• Canada
• Mexico
Europe
• Germany
• Spain
• United Kingdom
• France
• Italy
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
The report also includes profiles and for some of the leading companies in the Respiratory Drug Delivery Technologies Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies
• AptarGroup, Inc.
• AstraZeneca plc.
• Boehringer Ingelheim GmbH
• Cipla Limited
• Graham Field Health Products
• GSK Corporation
• Medisana GmbH.
• Merck & Co., Inc.
• Novartis AG
• Omron Corporation
• Philips Respironics
• Recipharm Ab.
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceuticals
• 3M Healthcare
Overall world revenue for Respiratory Drug Delivery Technologies Market, 2022 to 2032 in terms of value the market will surpass US$59.51 billion in 2022, our work calculates. We predict strong revenue growth through 2032. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Respiratory Drug Delivery Technologies Market, 2022 to 2032 Market report help you?
In summary, our 580+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Respiratory Drug Delivery Technologies Market, 2022 to 2032 Market, with forecasts, type company size each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2032 for 5 regional and 21 key national markets – See forecasts for the Respiratory Drug Delivery Technologies Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the Respiratory Drug Delivery Technologies Market, 2022 to 2032.
Read the full report: https://www.reportlinker.com/p06288089/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Nio (NYSE: NIO) stock surged Tuesday morning as the broader U.S. market rose, and was trading 10.2% higher as of 12:23 p.m. ET. Ironically, the electric vehicle (EV) maker just got a massive price target downgrade, but investors right now appear to care less about what analysts think and more about what's happening in Nio's home market of China. On Tuesday morning, Citigroup analyst Jeff Chung slashed his price target on Nio to $41.10 per share from $87 a share, according to TheFly.com.
Rogers knows a thing or two about making money in turbulent times.
Last month, the annualized rate of inflation hit 8.6%, the highest in more than 40 years. Last week, in response, the Federal Reserve bumped up its benchmark interest rate by 75 basis points, the largest such hike since 1994. The combination of high inflation and aggressive tightening action by the central bank sent an already jittery stock market to its worst single week since the onset of the COVID crisis, and has economists talking gloomily about a repeat of the late 1970s and early 1980s, wh
A market rally attempt gained steam as Tesla jumped but investors should be wary. Fed chief Jerome Powell is on tap again.
The Dow Jones rallied as stocks struck back. Tesla spiked even as Elon Musk issued a warning. Bitcoin bounced. Apple stock rose.
Since hitting their respective all-time closing highs, the 126-year-old Dow Jones Industrial Average, benchmark S&P 500, and growth-focused Nasdaq Composite have respectively fallen by as much as 19%, 24%, and 34%. This means the Nasdaq and S&P 500 are officially in the grip of a bear market. To make matters worse, there's the growing likelihood that the U.S. could enter a recession.
(Bloomberg) — When Shutterfly decided recently to move the database where it clusters reams of customer photos to the cloud, one name was noticeably absent from its list of potential providers: Oracle Corp.Most Read from BloombergSwitzerland Imports Russian Gold for First Time Since WarLiz Cheney Is Paying the Price in Her Home State for Crossing TrumpStocks Surge After $2 Trillion Wipeout; Bonds Fall: Markets WrapElon Musk Sounds Off on Recession Risk, Twitter Deal and TrumpMortgage Lenders Ti
If you’re thinking of pulling your 401(k) out of the stock market, or you’re too terrified to invest more, you need to meet my friend Betty Badluck. Poor old Betty has had the worst luck of any stock market investor you’ve ever met. In the last 40 years she has invested in the stock market just six times.
Morgan Stanley's chief executive officer James Gorman was the latest prominent executive to warn of a coming recession, saying at a June 13 financial conference, "It's possible we go into recession, obviously, probably 50-50 odds now." Ultra-high-yield dividend stocks can be a good place to run for cover during turbulent markets. Investors with an extra $134,200 in capital lying around to evenly split between these two quality income stocks could generate growing five-figure annual dividend income in the years ahead.
Kellogg CEO Steve Cahillane reveals his thinking behind his decision to break up the iconic food maker.
Elon Musk's clarification about the electric vehicle company's layoffs sent the stock higher.
The Biden administration is pushing hard to promote electric vehicles (EVs). From a $7.5 billion provision in the ‘Build Back Better’ bill to political pressure on automakers to commit to increased production with the goal of converting 40% of car sales to EVs by the end of this decade, it’s clear that under Biden, the government has the will to enforce a major shift in the automotive industry. The Biden administration has also prioritized the production of EV battery systems, to the tune of $3.
(Reuters) -A Black former elevator operator at Tesla Inc's flagship California assembly plant on Tuesday rejected a $15 million award in his lawsuit alleging racial abuse by coworkers, opening the door for a new trial after a judge slashed a $137 million jury verdict. Lawyers for Owen Diaz, who had sued Tesla in 2017, turned down the judge's award in a brief filing in federal court in San Francisco. "In rejecting the court’s excessive reduction by asking for a new trial, Mr. Diaz is again asking a jury of his peers to evaluate what Tesla did to him and to provide just compensation for the torrent of racist slurs that was directed at him," his lawyers said.
The fundamental "story" of Qualcomm seems to be in flux right now with a sell side fundamental analyst telling clients that the company has weakness in the handset area, while the CEO says the opposite. The On-Balance-Volume (OBV) line has moved sideways since January even though prices have declined – this is a bullish divergence. If we drew a downward sloping channel from January we would find that the most recent decline in June has not touched the "return line" of the channel (not drawn).
Oil prices skidded in early trade on Wednesday amid a push by U.S. President Joe Biden to bring down soaring fuel costs, including pressure on major U.S. firms to help ease the pain for drivers during the country's peak summer demand. U.S. West Texas Intermediate (WTI) crude futures fell $1.34, or 1,2%, to $108.18 a barrel at 0031 GMT, while Brent crude futures dropped $1.33, or 1.2%, to $113.32 a barrel. As the United States struggles to tackle soaring gasoline prices and inflation, U.S. President Joe Biden is expected on Wednesday to call for temporarily suspending the 18.4-cents a gallon federal tax on gasoline, a source briefed on the plan told Reuters.
Here's what a fundamental and technical analysis says about Google stock. GOOGL stock buybacks remain high as web search and YouTube advertising rebound. But cloud computing growth is key.
(Bloomberg) — Lennar Corp. has started trimming prices and offering buyer incentives in some areas of the US to bolster sales in a cooling housing market.Most Read from BloombergSwitzerland Imports Russian Gold for First Time Since WarLiz Cheney Is Paying the Price in Her Home State for Crossing TrumpStocks Surge After $2 Trillion Wipeout; Bonds Fall: Markets WrapElon Musk Sounds Off on Recession Risk, Twitter Deal and TrumpMortgage Lenders Timed the Market PerfectlyRapidly rising mortgage rate
(Bloomberg) — Two of Amazon.com Inc.’s top Black executives are leaving amid a management shakeup as Chief Executive Officer Andy Jassy puts his stamp on the company about a year into his tenure.Most Read from BloombergSwitzerland Imports Russian Gold for First Time Since WarLiz Cheney Is Paying the Price in Her Home State for Crossing TrumpStocks Surge After $2 Trillion Wipeout; Bonds Fall: Markets WrapElon Musk Sounds Off on Recession Risk, Twitter Deal and TrumpMortgage Lenders Timed the Mar
(Bloomberg) — Sam Bankman-Fried, the crypto billionaire who co-founded digital-asset exchange FTX Trading Ltd., is providing credit lines to try to stem contagions for his beleaguered industry. Most Read from BloombergSwitzerland Imports Russian Gold for First Time Since WarLiz Cheney Is Paying the Price in Her Home State for Crossing TrumpStocks Surge After $2 Trillion Wipeout; Bonds Fall: Markets WrapElon Musk Sounds Off on Recession Risk, Twitter Deal and TrumpMortgage Lenders Timed the Mark
Wes Crill, Dimensional Fund Advisors Head of Investments Strategists & Vice President, sits down with Yahoo Finance Live to discuss what to take away from today's market rally, recession indicators, inflation risks, and the relationship between the Fed's interest rate hikes and the housing market.